<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755441</url>
  </required_header>
  <id_info>
    <org_study_id>PFBIO</org_study_id>
    <nct_id>NCT02755441</nct_id>
  </id_info>
  <brief_title>Pulmonary Fibrosis Biomarker Cohort - a Prospective Cohort of Incident Patients With IPF</brief_title>
  <acronym>PFBIO</acronym>
  <official_title>Pulmonary Fibrosis Biomarker Cohort (PFBIO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nils Hoyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incident patients with idiopathic pulmonary fibrosis (IPF) in Denmark will be offered&#xD;
      inclusion and followed up for up to 5 years with measurements of blood biomarkers and&#xD;
      measurements of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPF pathogenesis is complex, including epithelial injury, resident fibroblast-myofibroblast&#xD;
      transformation, recruitment of fibrocytes, macrophage activation, and release of numerous&#xD;
      cytokines and chemokines. Several of these processes release potential biomarker proteins&#xD;
      into the blood stream or onto the epithelial surface where they can be measured. Biomarkers&#xD;
      have mainly two potential roles in IPF. Firstly, a diagnostic biomarker would distinguish IPF&#xD;
      from other diseases with similar symptoms, facilitating diagnosis and possibly decreasing the&#xD;
      need for risky procedures, such as surgical lung biopsy. Secondly, a prognostic biomarker&#xD;
      would distinguish rapid progressors from slow progressors, which is difficult today.&#xD;
&#xD;
      This study will prospectively include patients at the two largest centres in Denmark where&#xD;
      patients are treated for IPF and has thus a good opportunity to include the majority of&#xD;
      incident cases of IPF in Denmark. The blood levels of several promising biomarkers will be&#xD;
      measured at baseline and during up to 5 years follow-up. Patients will also be followed up&#xD;
      through regular clinical examination and by querying national registries to determine disease&#xD;
      progression, mortality, healthcare utilization and selected co-morbidities. The database will&#xD;
      be used for determination of risk factors for the outcomes listed above. Sub-group analyses&#xD;
      are planned in respect to sex, treatment, radiologic imaging, smoking status, clinical data&#xD;
      such as pulmonary function tests, co-morbidities (both pulmonary disease and extra-pulmonary&#xD;
      disease), and disease severity at baseline.&#xD;
&#xD;
      A research biobank with blood samples is established from the study population. This biobank,&#xD;
      and the database of newly diagnosed IPF patients, will be used for future research in IPF.&#xD;
&#xD;
      The prospectively created database will also be used for future research in IPF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression or mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who fulfil any of the following: disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of respiratory and non-respiratory hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of acute exacerbations of idiopathic pulmonary fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function tests</measure>
    <time_frame>1 year</time_frame>
    <description>Reduction in diffusion capacity (DLCO) and forced vital capacity (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause and disease-specific mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Change in St. George Respiratory Questionnaire, symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined end-point of disease progression</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who fulfill any of the following: decrease in lung function, reduced walking distance at 6 minutes walking test, increased need for supplementary oxygen, hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression in serum/plasma biomarker levels</measure>
    <time_frame>1 year</time_frame>
    <description>Increase or decrease in serum/plasma biomarker levels.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and EDTA-plasma is collected from all patients at 0, 6 and 12 months, 2 years, 3 years,&#xD;
      4 years and 5 years.&#xD;
&#xD;
      Blood DNA and RNA tubes are collected for all patients at one site (Gentofte hospital)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Incidental patients diagnosed with idiopathic pulmonary fibrosis (IPF) at Gentofte hospital&#xD;
        and Aarhus university hospital are screened for inclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic pulmonary fibrosis according to the 2011 guidelines by the&#xD;
             American Thoracic Cosicety (ATS) and European Respiratory Society (ERS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age lower than 18 years&#xD;
&#xD;
          -  Unable to provide informed consent to participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Hoyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nils Hoyer, MD</last_name>
    <phone>+45-38674200</phone>
    <email>nils.hoyer@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Hoyer, MD</last_name>
      <phone>+45-38674200</phone>
      <email>nils.hoyer@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.</citation>
    <PMID>21471066</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Nils Hoyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diagnosis</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

